DRAGONFLY's mission is to revolutionize disease treatment by developing advanced immunotherapies for vastly improved patient outcomes.
​
We build drugs in autoimmune disease, oncology, fibrosis, neuro-inflammation, neurology, and beyond.
In collaboration with AbbVie, BMS, Gilead and Merck, our novel TriNKET® and CYTOKINE platforms have generated Drug Candidates to target challenging diseases in a variety of therapeutic areas.
Engaging the Immune
System to Fight Disease
Our Collaborations
DRAGONFLY is a distinctively effective pharma partner.
Dragonfly rapidly develops drugs with our pharma partners in expanding fields from autoimmune disease and oncology, to neuro-inflammation, neuromuscular disease, virology, and beyond.
Growing the
Pipeline for Patients
In addition to a set of advanced programs in the clinic or handed off to our pharma partners, DRAGONFLY is developing 30+ TriNKETs® and multiple CYTOKINES across a broad range of fields, including autoimmune and inflammatory diseases, fibrosis, neurology, infectious disease, and oncology.
DRAGONFLY's pipeline is rapidly growing in a number of
therapeutic areas of critical patient need.
